# | Date | Analyst Firm | Upside/Downside | Price Target Change | Rating Change | Current Rating |
---|
Replimune reported that the IGNYTE clinical trial of RP1 plus nivolumab in anti-PD1 failed melanoma showed a 33.6% response rat...
-- Investigator-assessed 12-month results from the IGNYTE clinical trial of RP1 plus nivolumab in anti-PD-1 failed melanoma dem...
https://www.benzinga.com/secfilings/24/05/38870181/replimune-group-inc-general-corporate-statement-form8